INT37394

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.34
First Reported 1986
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 9
Total Number 9
Disease Relevance 6.41
Pain Relevance 2.11

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
platelet 2
stromal cell 1
monocytes 1
ECs 1
smooth muscle cells 1
ecs (Mus musculus)
Pain Link Frequency Relevance Heat
bradykinin 2 98.86 Very High Very High Very High
agonist 45 96.56 Very High Very High Very High
depression 5 94.96 High High
Inflammation 97 93.72 High High
Endogenous opioid 4 93.52 High High
Morphine 7 90.64 High High
chemokine 69 88.76 High High
Opioid 4 84.80 Quite High
Arthritis 29 80.92 Quite High
narcan 1 79.60 Quite High
Disease Link Frequency Relevance Heat
Cancer 828 99.64 Very High Very High Very High
Metastasis 101 99.12 Very High Very High Very High
Vasculitis 4 98.20 Very High Very High Very High
Mouth Cancer 19 97.20 Very High Very High Very High
Increased Venous Pressure Under Development 47 95.44 Very High Very High Very High
Depression 5 94.96 High High
Synovitis 4 94.16 High High
INFLAMMATION 100 93.72 High High
Recurrence 16 92.20 High High
Heart Rate Under Development 13 91.76 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Nonetheless, ECS and other forms of SIA, such as cold water exposure and restraint, share with ECS a common history of clinical use in the treatment of human depression.
Localization (forms) of ECS associated with depression
1) Confidence 0.34 Published 1986 Journal Ann. N. Y. Acad. Sci. Section Abstract Doc Link 3524381 Disease Relevance 0.24 Pain Relevance 0.83
The process of angiogenesis, that is the formation of new blood vessels from existing vasculature, involves complex interplay among cancer and stromal cell-secreted factors, extracellular matrix (ECM) constituents, and endothelial cells (ECs) (Figure 1).
Localization (secreted) of ECs in stromal cell associated with cancer
2) Confidence 0.05 Published 2010 Journal PPAR Research Section Body Doc Link PMC2829627 Disease Relevance 0.83 Pain Relevance 0.12
Because the presence of ECS has been identified as an indicator of poor prognosis, patients with ECS are commonly treated with adjuvant therapy, including radiotherapy and chemoradiotherapy.
Localization (presence) of ECS
3) Confidence 0.04 Published 2010 Journal Eur Arch Otorhinolaryngol Section Body Doc Link PMC2874025 Disease Relevance 1.34 Pain Relevance 0
Within a given microenvironment, the angiogenic response is determined by a net balance between pro- and anti-angiogenic regulators released from activated ECs, monocytes, smooth muscle cells and platelets.
Localization (released) of ECs in platelets
4) Confidence 0.04 Published 2004 Journal J Transl Med Section Body Doc Link PMC455695 Disease Relevance 0.39 Pain Relevance 0
The mechanism of action of captopril, an ACEI, involves suppression of angiotensin II, a potent vasoconstrictor, and increased levels of bradykinin through the inhibition of kininase II, which induces NO release in ECs and stimulates the production of prostacyclin, a vasodilating prostaglandin [117].
Neg (NO) Localization (release) of ECs associated with bradykinin
5) Confidence 0.03 Published 2010 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2930857 Disease Relevance 1.13 Pain Relevance 0.17
Within a given microenvironment, the angiogenic response is determined by a net balance between pro- and anti-angiogenic regulators released from activated ECs, monocytes, smooth muscle cells and platelets.
Localization (released) of ECs in monocytes
6) Confidence 0.01 Published 2004 Journal J Transl Med Section Body Doc Link PMC455695 Disease Relevance 0.39 Pain Relevance 0
Within a given microenvironment, the angiogenic response is determined by a net balance between pro- and anti-angiogenic regulators released from activated ECs, monocytes, smooth muscle cells and platelets.
Localization (released) of ECs in smooth muscle cells
7) Confidence 0.01 Published 2004 Journal J Transl Med Section Body Doc Link PMC455695 Disease Relevance 0.39 Pain Relevance 0
Significant release of NO from ECs stimulated with lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma) occurred after 2 h after exposure and remained significantly increased over basal levels for 24-48 h (28 nM), consistent with iNOS activation.
Localization (release) of ECs in ECs
8) Confidence 0.01 Published 1998 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 9641464 Disease Relevance 0.13 Pain Relevance 0.47
ECs secrete several vasodilatory mediators, including nitric oxide, prostacyclin (PGI2), platelet-activating factor, histamine, and others [4-6].
Localization (secrete) of ECs in platelet
9) Confidence 0.01 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2592799 Disease Relevance 1.56 Pain Relevance 0.52

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox